BCHT was established in March 2004 by the investment of Changchun High-technology Industry Development Property (Group). The company is a high-tech enterprise engaged in research, development, production and marketing of biologics and drugs. In 2010, gelatin-free lyophilized attenuated live varicella vaccine was launched to the market, which opened a new time for safe immunization. In 2011, the extension of the vaccine shelf-life was up to 36 months which is the longest one in the world.

Jilin Maifeng Biopharmaceutical Co., Ltd., a subsidiary of BCHT, is devoted to mostly R&D in high density cell culture technique and its application for large scale production. Jilin Maifeng is the first company to develop and apply the self-developed microcarrier bioreactor technology to produce rabies vaccine for human use.

Changchun Beyel Pharmaceutical Co., Ltd., a subsidiary of BCHT, is engaged in manufacturing of API and formulation of peptide drugs which are developed by Center for Drug Research and Development in the consortium. It is a new growing business area for BCHT.

BCHT is in a fast-growing stage to approach the advanced international level in quality, marketing, management and human resource, aiming at becoming a first-class biopharmaceutical enterprise in the world.